Immunovant (IMVT) vs Kodiak Sciences (KOD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Immunovant (IMVT) over the past year, gaining 367.8% versus a gain of 40.6%. Over five years, IMVT leads with a +308.9% price change compared with +3.0% for KOD. Immunovant is the larger company by market cap ($6.57 billion vs $6.35 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMVT | KOD |
|---|---|---|
| Share price | $31.77 | $97.17 |
| Market cap | $6.57B | $6.35B |
| 1-day change | -2.31% | -0.75% |
| YTD return | +24.98% | +247.53% |
| 1-year return | +40.64% | +367.84% |
| 5-year return | +308.88% | +3.04% |
| EPS (TTM) | $-2.56 | $-4.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-505.61M | $-229.97M |
| 52-week high | $45.42 | $112.79 |
| 52-week low | $21.93 | $20.38 |
| Distance from 52-week high | -30.05% | -13.85% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +53.07% | +33.27% |
| Average volume | 1.42M | 1.77M |
| Shares outstanding | 206.95M | 65.40M |
| Employees | 315 | 144 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed IMVT by 327.2 percentage points over the past year.
About Immunovant
IMVT stock →Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
IMVT vs KOD FAQ
Which is bigger, Immunovant or Kodiak Sciences?
Immunovant (IMVT) is larger, with a market capitalization of $6.57B compared with $6.35B for Kodiak Sciences (KOD).
Which stock has performed better over the past year, IMVT or KOD?
KOD returned +367.84% over the past 12 months, compared with +40.64% for IMVT (price return, excluding dividends). Past performance does not predict future results.
Are Immunovant and Kodiak Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.